Therapy News and Research

RSS

GLP-1 receptor agonists associated with reduced BMI in adolescents with severe obesity

Preliminary evidence from a clinical trial suggests that treatment with glucagon-like peptide-1 (GLP-1) receptor agonists was associated with reduced body mass index and body weight in adolescents with severe obesity, according to a report published Online First by JAMA Pediatrics, a JAMA Network publication.

5 Feb 2013

Results from Merck’s Vorinostat phase 1 trial on lymphoma

Patients whose aggressive lymphomas have relapsed or failed to respond to the current front-line chemotherapy regimen now have an effective second line of attack against their disease.

5 Feb 2013

Orphan, St George's sign licensing agreement to develop new therapies for metabolic disorders

St George's, University of London has signed an exclusive worldwide licensing agreement with rare-disease research-and-development firm Orphan Technologies Ltd to develop new therapies for deadly metabolic disorders.

5 Feb 2013

UPCI researchers uncover new technique to stop growth of cancer cells

University of Pittsburgh Cancer Institute (UPCI) researchers have uncovered a technique to halt the growth of cancer cells, a discovery that led them to a potential new anti-cancer therapy.

5 Feb 2013

ATI Neurostimulation System demonstrates clinical effectiveness in treating cluster headache

Autonomic Technologies, Inc. (ATI), the developer of the ATI Neurostimulation System designed for the treatment of severe headaches, today announced results of their clinical study in cluster headache, now published online in Cephalalgia.

5 Feb 2013

NeuroSigma receives third NIH grant to develop subcutaneous trigeminal nerve stimulation for DRE

NeuroSigma, Inc., a California-based medical device company, today announced it received a Notice of Award, for a Fast Track Small Business Innovation Research (SBIR) grant, from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH).

5 Feb 2013

Loyola Flu Central now available on LUHS web site

Loyola Flu Central, a weekly snapshot of flu activity locally, regionally and nationally is now available on the Loyola University Health System web site, through Twitter and on Facebook.

5 Feb 2013

The Journal of Urology publishes results from BioSpecifics XIAFLEX trials on Peyronie's disease

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX in the U.S. and XIAPEX in Europe and Eurasia, today announced that The Journal of Urology has electronically published the uncorrected proof of the pivotal IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials on its website.

5 Feb 2013

PET with 11C-PIB can positively visualize amyloid deposits in the heart

While amyloid imaging may now be most associated with detecting plaques in the brain, it has the potential to change the way cardiac amyloidosis is diagnosed. According to first-of-its-kind research published in the February issue of The Journal of Nuclear Medicine, positron emission tomography (PET) with 11C-PIB can positively visualize amyloid deposits in the heart.

5 Feb 2013

Novian Health completes $11M funding round

Novian Health, developer of Novilase Breast Therapy, announced today that it has successfully completed a funding round totaling $11 million.

5 Feb 2013

New gold nanoparticle can transport powerful radioactive particles directly to tumors

We've all heard that "it's not wise to use a cannon to kill a mosquito." But what if you could focus the cannon's power to concentrate power into a tiny space? In a new study, University of Missouri researchers have demonstrated the ability to harness powerful radioactive particles and direct them toward small cancer tumors while doing negligible damage to healthy organs and tissues.

5 Feb 2013

Immune system can use melanoma's own proteins to kill off cancer cells

Though a small group of proteins, the family called Ras controls a large number of cellular functions, including cell growth, differentiation, and survival. And because the protein has a hand in cellular division, mutated Ras, which can be detected in one-third of all tumors, contributes to many human cancers by allowing for the rapid growth of diseased cells.

5 Feb 2013

Gilead Sciences fourth quarter total revenues increase 18% to $2.59 billion

Gilead Sciences, Inc. announced today its results of operations for the fourth quarter and full year 2012.

5 Feb 2013

BrainStorm initiates NurOwn Phase IIa dose-escalating trial in ALS

BrainStorm Cell Therapeutics, a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the first patient began treatment in the Company's Phase IIa dose-escalating clinical trial for ALS.

5 Feb 2013

Topline results from Gilead’s FISSION and NEUTRINO Phase 3 studies on HCV infection

Gilead Sciences today announced topline results from two Phase 3 studies, FISSION and NEUTRINO, evaluating a 12-week course of the once-daily nucleotide sofosbuvir in combination with ribavirin (FISSION) and in combination with ribavirin and pegylated interferon (NEUTRINO) among treatment-naïve patients with chronic hepatitis C virus (HCV) infection.

5 Feb 2013

ZirMed releases Clinical Link for healthcare providers

ZirMed, Inc. announces the release of a secure, national information exchange for healthcare providers. The innovative solution, called ZirMed Clinical Link harnesses the power of ZirMed's connected network of healthcare providers facilitating secure provider-to-provider communications from any EMR or information management system via ZirMed's software-as-a-service (SaaS) platform.

4 Feb 2013

Viewpoints: Obama's 'olive branch' on birth control coverage; Sen. Kirk recounts his stroke therapy; Nurses oppose mandatory flu shots

The Obama administration released the final details Friday of the exemption it will provide religious-affiliated employers from the requirement to include free birth control in employees' insurance policies. Not surprisingly, the announcement didn't seem to mollify any of the critics who'd been arguing that the exemption was inadequate.

4 Feb 2013

Therapy News and Research

GLP-1 receptor agonists associated with reduced BMI in adolescents with severe obesity

Results from Merck’s Vorinostat phase 1 trial on lymphoma

Orphan, St George's sign licensing agreement to develop new therapies for metabolic disorders

UPCI researchers uncover new technique to stop growth of cancer cells

ATI Neurostimulation System demonstrates clinical effectiveness in treating cluster headache

NeuroSigma receives third NIH grant to develop subcutaneous trigeminal nerve stimulation for DRE

Loyola Flu Central now available on LUHS web site

The Journal of Urology publishes results from BioSpecifics XIAFLEX trials on Peyronie's disease

PET with 11C-PIB can positively visualize amyloid deposits in the heart

Novian Health completes $11M funding round

New gold nanoparticle can transport powerful radioactive particles directly to tumors

Immune system can use melanoma's own proteins to kill off cancer cells

Gilead Sciences fourth quarter total revenues increase 18% to $2.59 billion

BrainStorm initiates NurOwn Phase IIa dose-escalating trial in ALS

Topline results from Gilead’s FISSION and NEUTRINO Phase 3 studies on HCV infection

ZirMed releases Clinical Link for healthcare providers

Viewpoints: Obama's 'olive branch' on birth control coverage; Sen. Kirk recounts his stroke therapy; Nurses oppose mandatory flu shots

Interferon retreatment warning in HCV

Risk factors for death after COPD hospitalization identified

Oral toxicity is frequent limitation of mTOR therapy

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News